ExploRNA Therapeutics Partners with Łukasiewicz - IChP for GMP Cap Analog Production
News related to:ExploRNA Therapeutics · 2 min read
WARSAW, Poland, Sept. 22, 2026 /CourierPR/ -- ExploRNA Therapeutics, a biotechnology company specializing in novel mRNA capping technologies, has entered into a strategic partnership with the Łukasiewicz Research Network, Industrial Chemistry Institute (Łukasiewicz - IChP). This collaboration aims to advance the production of GMP (Good Manufacturing Practice) grade cap analogs, including the company’s proprietary AvantCap Q1 technology.
The partnership is a significant step for ExploRNA as it ensures a reliable supply of high-quality raw materials for its clients. Co-transcriptional capping is a critical process in mRNA manufacturing, directly influencing the yield, quality, and translation efficiency of the final drug product. By partnering with Łukasiewicz - IChP, a renowned institution in advanced chemical synthesis and production scaling, ExploRNA can now provide its industry partners with premium-grade cap analogs, facilitating the advancement of their clinical programs and commercial pipelines.
ExploRNA Therapeutics focuses on developing state-of-the-art mRNA capping technologies and platform solutions, aiming to significantly enhance mRNA translational efficiency for next-generation genetic medicines. The company's proprietary AvantCap Q1 technology is designed to improve the efficiency and quality of mRNA therapeutics and vaccines, making it a valuable asset in the rapidly evolving biopharmaceutical landscape.
Łukasiewicz - IChP, on the other hand, is a leading Polish research and development center specializing in chemical synthesis, process engineering, and scaling up production for the pharmaceutical and advanced chemical industries. The partnership between the two organizations will leverage Łukasiewicz - IChP's advanced capabilities in chemical synthesis and production scaling to produce GMP-grade cap analogs, ensuring that ExploRNA's clients have access to the highest quality materials for their mRNA therapeutics and vaccines.
The production of GMP-grade materials is crucial for the ongoing advancement of ExploRNA's commercial strategy, allowing the company to support global biotech and pharmaceutical developers from early-stage research through to late-stage clinical trials and full-scale commercialization. This partnership underscores the commitment of both organizations to advancing the field of mRNA technology and delivering innovative solutions to the biopharmaceutical industry.
In conclusion, the strategic partnership between ExploRNA Therapeutics and Łukasiewicz - IChP is a significant development in the biotechnology sector, providing a robust supply chain for high-quality cap analogs. This collaboration is expected to enhance the efficiency and quality of mRNA therapeutics and vaccines, driving innovation and progress in the field.